“…The inevitable formation of multiple isomers differing in their pharmacokinetics [10] aroused interest in developing an alternative '3+1' approach, in which a neutral oxometal complex in a distorted square pyramidal or trigonal bipyramidal molecular geometry was prepared by employing the mixed tridentate (SNS, ONS, ONO or SSS) ligand and mondentate thiol ligand with the appropriate MO 3+ precursors [11][12][13][14]. These '3+1' integrated complexes eliminated the possibility of syn and anti stereoisomers that are often produced in the tetradentate complexes, but they were found to be relatively unstable in vitro and in vivo due to metabolism and replacement of the monothiol ligand through transchelation by physiological thiols such as cysteine and glutathione [15].…”